vs
Side-by-side financial comparison of Ameren (AEE) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.8B, roughly 1.6× Ameren). Ameren runs the higher net margin — 14.2% vs -3.7%, a 17.9% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs -8.2%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $-54.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -0.9%).
Ameren Corporation, together with its subsidiaries, operates as a public utility holding company in the United States. It operates through four segments: Ameren Missouri, Ameren Illinois Electric Distribution, Ameren Illinois Natural Gas, and Ameren Transmission. The company engages in the rate-regulated electric generation, transmission, and distribution activities; and rate-regulated natural gas distribution and transmission businesses. It primarily generates electricity through coal, nucle...
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
AEE vs BHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $2.8B |
| Net Profit | $253.0M | $-103.0M |
| Gross Margin | — | — |
| Operating Margin | 20.2% | 17.0% |
| Net Margin | 14.2% | -3.7% |
| Revenue YoY | -8.2% | 9.3% |
| Net Profit YoY | 21.6% | -205.1% |
| EPS (diluted) | $0.92 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.8B | $2.8B | ||
| Q3 25 | $2.7B | $2.7B | ||
| Q2 25 | $2.2B | $2.5B | ||
| Q1 25 | $2.1B | $2.3B | ||
| Q4 24 | $1.9B | $2.6B | ||
| Q3 24 | $2.2B | $2.5B | ||
| Q2 24 | $1.7B | $2.4B | ||
| Q1 24 | $1.8B | $2.2B |
| Q4 25 | $253.0M | $-103.0M | ||
| Q3 25 | $641.0M | $179.0M | ||
| Q2 25 | $277.0M | $148.0M | ||
| Q1 25 | $290.0M | $-58.0M | ||
| Q4 24 | $208.0M | $98.0M | ||
| Q3 24 | $457.0M | $-85.0M | ||
| Q2 24 | $260.0M | $10.0M | ||
| Q1 24 | $262.0M | $-64.0M |
| Q4 25 | 20.2% | 17.0% | ||
| Q3 25 | 30.6% | 23.1% | ||
| Q2 25 | 18.5% | 17.5% | ||
| Q1 25 | 20.5% | 12.2% | ||
| Q4 24 | 10.2% | 21.8% | ||
| Q3 24 | 27.0% | 12.7% | ||
| Q2 24 | 21.3% | 16.2% | ||
| Q1 24 | 20.4% | 13.1% |
| Q4 25 | 14.2% | -3.7% | ||
| Q3 25 | 23.7% | 6.7% | ||
| Q2 25 | 12.5% | 5.8% | ||
| Q1 25 | 13.8% | -2.6% | ||
| Q4 24 | 10.7% | 3.8% | ||
| Q3 24 | 21.0% | -3.4% | ||
| Q2 24 | 15.4% | 0.4% | ||
| Q1 24 | 14.4% | -3.0% |
| Q4 25 | $0.92 | $-0.30 | ||
| Q3 25 | $2.35 | $0.48 | ||
| Q2 25 | $1.01 | $0.40 | ||
| Q1 25 | $1.07 | $-0.16 | ||
| Q4 24 | $0.77 | $0.24 | ||
| Q3 24 | $1.70 | $-0.23 | ||
| Q2 24 | $0.97 | $0.03 | ||
| Q1 24 | $0.98 | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.0M | $1.3B |
| Total DebtLower is stronger | $19.4B | $20.8B |
| Stockholders' EquityBook value | $13.4B | $-554.0M |
| Total Assets | $48.5B | $26.4B |
| Debt / EquityLower = less leverage | 1.45× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.0M | $1.3B | ||
| Q3 25 | $9.0M | $1.3B | ||
| Q2 25 | $11.0M | $1.7B | ||
| Q1 25 | $23.0M | $1.1B | ||
| Q4 24 | $7.0M | $1.2B | ||
| Q3 24 | $17.0M | $719.0M | ||
| Q2 24 | $19.0M | $595.0M | ||
| Q1 24 | $85.0M | $733.0M |
| Q4 25 | $19.4B | $20.8B | ||
| Q3 25 | — | $21.0B | ||
| Q2 25 | — | $21.7B | ||
| Q1 25 | — | $21.5B | ||
| Q4 24 | $17.8B | $21.6B | ||
| Q3 24 | — | $21.5B | ||
| Q2 24 | — | $21.7B | ||
| Q1 24 | — | $22.1B |
| Q4 25 | $13.4B | $-554.0M | ||
| Q3 25 | $12.8B | $-565.0M | ||
| Q2 25 | $12.3B | $-764.0M | ||
| Q1 25 | $12.2B | $-1.2B | ||
| Q4 24 | $12.1B | $-1.3B | ||
| Q3 24 | $11.8B | $-1.2B | ||
| Q2 24 | $11.5B | $-1.2B | ||
| Q1 24 | $11.4B | $-1.1B |
| Q4 25 | $48.5B | $26.4B | ||
| Q3 25 | $47.4B | $26.8B | ||
| Q2 25 | $46.6B | $27.3B | ||
| Q1 25 | $45.7B | $26.4B | ||
| Q4 24 | $44.6B | $26.5B | ||
| Q3 24 | $43.3B | $26.5B | ||
| Q2 24 | $42.3B | $26.5B | ||
| Q1 24 | $41.3B | $26.9B |
| Q4 25 | 1.45× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $956.0M | $495.0M |
| Free Cash FlowOCF − Capex | $-54.0M | $403.0M |
| FCF MarginFCF / Revenue | -3.0% | 14.4% |
| Capex IntensityCapex / Revenue | 56.7% | 3.3% |
| Cash ConversionOCF / Net Profit | 3.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-775.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $956.0M | $495.0M | ||
| Q3 25 | $1.1B | $405.0M | ||
| Q2 25 | $862.0M | $289.0M | ||
| Q1 25 | $431.0M | $211.0M | ||
| Q4 24 | $817.0M | $601.0M | ||
| Q3 24 | $897.0M | $405.0M | ||
| Q2 24 | $557.0M | $380.0M | ||
| Q1 24 | $492.0M | $211.0M |
| Q4 25 | $-54.0M | $403.0M | ||
| Q3 25 | $116.0M | $314.0M | ||
| Q2 25 | $-204.0M | $190.0M | ||
| Q1 25 | $-633.0M | $96.0M | ||
| Q4 24 | $-473.0M | $495.0M | ||
| Q3 24 | $-240.0M | $334.0M | ||
| Q2 24 | $-445.0M | $302.0M | ||
| Q1 24 | $-398.0M | $129.0M |
| Q4 25 | -3.0% | 14.4% | ||
| Q3 25 | 4.3% | 11.7% | ||
| Q2 25 | -9.2% | 7.5% | ||
| Q1 25 | -30.2% | 4.2% | ||
| Q4 24 | -24.4% | 19.3% | ||
| Q3 24 | -11.0% | 13.3% | ||
| Q2 24 | -26.3% | 12.6% | ||
| Q1 24 | -21.9% | 6.0% |
| Q4 25 | 56.7% | 3.3% | ||
| Q3 25 | 36.6% | 3.4% | ||
| Q2 25 | 48.0% | 3.9% | ||
| Q1 25 | 50.7% | 5.1% | ||
| Q4 24 | 66.5% | 4.1% | ||
| Q3 24 | 52.3% | 2.8% | ||
| Q2 24 | 59.2% | 3.2% | ||
| Q1 24 | 49.0% | 3.8% |
| Q4 25 | 3.78× | — | ||
| Q3 25 | 1.72× | 2.26× | ||
| Q2 25 | 3.11× | 1.95× | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | 3.93× | 6.13× | ||
| Q3 24 | 1.96× | — | ||
| Q2 24 | 2.14× | 38.00× | ||
| Q1 24 | 1.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AEE
Segment breakdown not available.
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
